Research programme: apolipoprotein A1 - BioDelivery Sciences
Alternative Names: Apolipoprotein A1 research programme - BioDelivery SciencesLatest Information Update: 24 Mar 2022
At a glance
- Originator BioDelivery Sciences International
- Class
- Mechanism of Action Apolipoprotein A-I stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Atherosclerosis
Most Recent Events
- 22 Mar 2022 BioDelivery Sciences International has been acquired by Collegium Pharmaceutical
- 20 Apr 2004 Preclinical trials in Atherosclerosis in USA (PO)